CN104352490A - Compound amoxicillin sodium injection - Google Patents
Compound amoxicillin sodium injection Download PDFInfo
- Publication number
- CN104352490A CN104352490A CN201410652953.6A CN201410652953A CN104352490A CN 104352490 A CN104352490 A CN 104352490A CN 201410652953 A CN201410652953 A CN 201410652953A CN 104352490 A CN104352490 A CN 104352490A
- Authority
- CN
- China
- Prior art keywords
- amoxicillin sodium
- injection
- berberine
- parts
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a compound amoxicillin sodium injection with a synergistic antibacterial effect. The composition comprises the following components in parts by weight: 1-4 parts of amoxicillin sodium, 1-2 parts of berberine, 0.5-1 part of sodium sulfite, 0.5-1 part of glycine, 1-2 parts of Tween and 1-2 parts of PVP. The injection disclosed by the invention is high in stability, and simple in preparation process, has a good inhibiting effect on gram-negative bacillus, and a wide market prospect, and is capable of reducing the dosage of a single preparation and shortening the treatment cycle.
Description
Technical field
The present invention relates to a kind of animal-use drug, particularly relate to a kind of antibiotic compound preparation, especially in particular to the injection of a kind of Amoxicillin Sodium and berberine.
Background technology
Bacteriological infection is that pathogenic bacterium or conditioned pathogen invade growth and breeding in blood circulation, produce toxin and the acute systemic infection caused by other metabolites, clinically with shiver with cold, high heat, erythra, arthralgia and hepatosplenomegaly for feature, part can have septic shock and migrate sexually transmitted disease (STD) stove.The acute systemic infection that pathogenic microorganism causes from wound or In vivo infection focus intrusion blood.Also can there is agitation, extreme cold of the limbs and cyanosis, thready pulse speed, tachypnea, blood pressure drops etc. in some patients clinically.Especially there are chronic disease or immunologic hypofunction person, treat not in time and have complications, septicemia or pyemia can be developed into.
At present for the treatment of bacteriological infection, mainly contain the immunity of vaccine, the modes such as antibiotic, chemicals, Chinese medicine carry out prevention and therapy.Wherein vaccine immunization, because of enteric microorganism antigen and antigenic determinant complexity, immunologic mechanism is difference slightly, and immune effect is imprecise.Along with antibacterials abuse clinically, cause the drug resistance of antibacterial very general, as the curative effect of medication such as gentamycin, oxytetracycline, norfloxacin, norfloxacin conventional clinically reduces.Prevent with other, Therapeutic Method compares, Chinese herbal medicine has non-specific antimicrobial effect, and residual toxicity is lower, and animal generally not easily produces drug resistance to it.And Chinese medicine and Western medicine are carried out effective compatibility, the generation of Resistant strain can be slowed down.
Summary of the invention
The invention provides a kind of injection comprising an Amoxicillin Sodium and berberine with synergetic antibacterial effect, there is good inhibitory action to gram negative bacteria, greatly reduce the consumption of single preparations of ephedrine, good stability, not drug resistance, overcomes the deficiencies in the prior art part.
Technical scheme of the present invention is: a kind of compound amoxicillin sodium injection, it is characterized in that the parts by weight of each component in described compositions are: Amoxicillin Sodium 1-4 weight portion; Berberine 1-2 weight portion; Sodium sulfite 0.5-1 weight portion; Glycine 0.5-1 weight portion; Tween 1-2 weight portion; PVP1-2 part.The weight ratio of Amoxicillin Sodium and berberine is 1:1 or 2:1.Tween is selected from Tween 80 or polysorbas20.
Compared with the prior art, injection of amoxicillin sodium for injection provided by the invention and berberine and preparation method thereof, has the following advantages:
1, good stability: the compound injection of Amoxicillin Sodium provided by the invention and berberine, wrapped up and be adsorbed in nanoparticulate carriers material, its active component is effectively protected, therefore the more excellent commercially available product of stability is more excellent.Acceleration June and long-time stability are investigated result and are also shown that solution colour, pH value, related substance, content all do not have significant change, drastically increase medicine stability.
2, antibacterial activity is high: in the present invention, Amoxicillin Sodium and berberine coordinate with specific ratio, can produce cooperative effect, when reducing dosage, farthest plays Antifungal activity.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is described in further detail.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment.
Embodiment 1
Amoxicillin Sodium 100g
Berberine 100g
Tween 80 100g
Glycine 50g
Sodium sulfite 100g
PVP100g
Prepare 500 altogether
Head Amoxicillin Sodium, glycine and PVP are added successively in 300ml water for injection; By tween, sodium sulfite is dissolved in 400ml water for injection, slowly adds berberine to dissolving completely under stirring; Merge two parts of solution, mend and inject water to 1000ml, add active carbon and stir, filter, sterilizing, fill.
Embodiment 2
Amoxicillin Sodium 150g
Berberine 100g
Tween 80 100g
Sodium sulfite 50g
Glycine 50g
PVP50g
Prepare 500 altogether
Amoxicillin Sodium, glycine and PVP are added successively in 300ml water for injection; By tween, sodium sulfite is dissolved in 400ml water for injection, slowly adds berberine to dissolving completely under stirring; Merge two parts of solution, mend and inject water to 1000ml, add active carbon and stir, filter, sterilizing, fill.
Embodiment 3
Amoxicillin Sodium 200g
Berberine 100g
Polysorbas20 100g
Sodium sulfite 55g
Glycine 55g
PVP100g
Prepare 500 altogether
Amoxicillin Sodium, glycine and PVP are added successively in 300ml water for injection; By tween, sodium sulfite is dissolved in 400ml water for injection, slowly adds magnolol to dissolving completely under stirring; Merge two parts of solution, mend and inject water to 1000ml, add active carbon and stir, filter, sterilizing, fill.
Embodiment 4
Pharmacological evaluation: different ratio Amoxicillin Sodium and berberine in vitro activity
Materials and methods
1. test proportioning: following proportions by weight.
(1) Amoxicillin Sodium
(2) berberine
(2) Amoxicillin Sodium+berberine (1: 0.5)
(3) Amoxicillin Sodium+berberine (1: 1)
(4) Amoxicillin Sodium+berberine (2: 1)
(5) Amoxicillin Sodium+berberine (3: 1)
2. test strain:
Minimum inhibitory concentration (MIC) measures
Adopt meat soup trace doubling dilution, berberine and Amoxicillin Sodium being diluted with sterilizing M-H meat soup is the medicinal liquid of a series of concentration.Getting 100 μ l respectively adds in micro-hole, adds certain density bacterial suspension afterwards, makes final every hole concentration be 1.5 × 105CFU/ml, and antibacterial application liquid concentration is 37 DEG C of incubated overnight.Minimum antibiotic concentration without bacterial growth is minimum inhibitory concentration (MIC, mg/L).Result of the test is as following table:
As can be seen from the MIC data in upper table, the compound preparation that Amoxicillin Sodium+berberine is prepared according to a certain weight ratio is better than two kinds of folk prescription medicines far away to the inhibitory action of escherichia coli cvcc223, dosage reduces greatly, the compound preparation that both make can play antibacterial synergism, enhances antibacterial efficacy.
Claims (3)
1. a compound amoxicillin sodium injection, is characterized in that the parts by weight of each component in described injection are: Amoxicillin Sodium 1-4 weight portion; Berberine 1-2 weight portion; Sodium sulfite 0.5-1 weight portion; Glycine 0.5-1 weight portion; Tween 1-2 weight portion; PVP1-2 part.
2. injection as claimed in claim 1, is characterized in that the weight ratio of described Amoxicillin Sodium and berberine is 1:1 or 2:1.
3. injection as claimed in claim 1 or 2, is characterized in that described tween is selected from Tween 80 or polysorbas20.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410652953.6A CN104352490A (en) | 2014-11-13 | 2014-11-13 | Compound amoxicillin sodium injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410652953.6A CN104352490A (en) | 2014-11-13 | 2014-11-13 | Compound amoxicillin sodium injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104352490A true CN104352490A (en) | 2015-02-18 |
Family
ID=52519866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410652953.6A Pending CN104352490A (en) | 2014-11-13 | 2014-11-13 | Compound amoxicillin sodium injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104352490A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105853449A (en) * | 2016-05-06 | 2016-08-17 | 九江学院 | Combined antibacterial drug of amikacin sulfate for injection |
| CN105998029A (en) * | 2016-05-06 | 2016-10-12 | 九江学院 | Antibacterial composite drug of levofloxacin hydrochloride for injection |
| CN107569458A (en) * | 2017-10-10 | 2018-01-12 | 苏州二叶制药有限公司 | A kind of pharmaceutical composition of amoxicillin sodium and clavulanate potassium compound |
| CN114042067A (en) * | 2021-12-21 | 2022-02-15 | 江西利德菲生物药业有限公司 | Amoxicillin sodium for injection and preparation method thereof |
-
2014
- 2014-11-13 CN CN201410652953.6A patent/CN104352490A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105853449A (en) * | 2016-05-06 | 2016-08-17 | 九江学院 | Combined antibacterial drug of amikacin sulfate for injection |
| CN105998029A (en) * | 2016-05-06 | 2016-10-12 | 九江学院 | Antibacterial composite drug of levofloxacin hydrochloride for injection |
| CN105853449B (en) * | 2016-05-06 | 2018-10-30 | 九江学院 | A kind of antibacterial compound drug of amikacin sulfate for injection |
| CN107569458A (en) * | 2017-10-10 | 2018-01-12 | 苏州二叶制药有限公司 | A kind of pharmaceutical composition of amoxicillin sodium and clavulanate potassium compound |
| CN114042067A (en) * | 2021-12-21 | 2022-02-15 | 江西利德菲生物药业有限公司 | Amoxicillin sodium for injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yen et al. | Lactoferrin: an iron-binding antimicrobial protein against Escherichia coli infection | |
| CN103989728B (en) | It is a kind of to contain the livestock and poultry compound medicine containing pearl grass and beta-lactam class antimicrobial | |
| CN104352490A (en) | Compound amoxicillin sodium injection | |
| CN102008490B (en) | Compound florfenicol injection for animal | |
| CN102205126A (en) | Application of combined catechin matters together with antibacterial agents | |
| KR20230096025A (en) | Direct delivery of vitamins to inhibit microbial pathogens | |
| CN102058821A (en) | Application of tsaoko oil in preparation of medicament for treating bacterial infection diseases | |
| CN104352501B (en) | A kind of compound ceftiofur sodium injection | |
| CN104367577A (en) | Compound ofloxacin injection | |
| CN104352491A (en) | Compound amoxicillin sodium liposome drug and preparation method thereof | |
| CN102558307A (en) | Octapeptin as well as preparation and application thereof | |
| CN102847160B (en) | Compound quinolone injection for livestock, and preparation method thereof | |
| CN103110746A (en) | Effective antibacterial traditional chinese medicine composition | |
| CN105250387A (en) | Antibacterial Chinese herbal medicine compound for fishes as well as preparation method and application of antibacterial Chinese herbal medicine compound | |
| CN101249069A (en) | Tilmicosin long-acting injection and method of preparing the same | |
| KR101762798B1 (en) | Antibacterial pharmaceutical composition against Salmonella spp. comprosong glue extract | |
| CN107898801A (en) | Composition and its application containing rifamycin and lipiarmycin | |
| CN104523693A (en) | Antifungal compound preparation containing chlorogenic acid and application thereof | |
| Busi et al. | Antimicrobial photodynamic therapy: concepts and applications | |
| CN103356663A (en) | Sulfamonomethoxine-ciprofloxacin-fosfomycin combined injection for veterinary use and preparation method thereof | |
| CN102334712B (en) | Preparation method of solution for improving enteric microorganisms | |
| CN109464491B (en) | Myrobalan composition and application thereof in preparation of product for preventing and/or treating diarrhea and/or mastitis | |
| CN107137386B (en) | Medicine and composition for preventing and treating hippocampal gastroenteritis | |
| CN106983771B (en) | Medicine and composition for preventing and treating hippocampus head ulceration | |
| CN101879179A (en) | Compound Ofloxacin solution and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150218 |